{"transactions":[{"id":740922,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-13T01:57:29.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":2498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":2498,"derivative":{"underlying":"Common Stock","underlying_shares":2498},"source":{"system":"sec-edgar","filing":"0000950157-26-000718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015726000718/ownership.xml","form_type":"4"}},{"id":740921,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-13T01:57:29.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":false,"shares":2391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2391},"source":{"system":"sec-edgar","filing":"0000950157-26-000718","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015726000718/ownership.xml","form_type":"4"}},{"id":740920,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-13T01:57:29.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":true,"shares":2391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares are held via CHESS Depositary Interests (\"CDIs\"), which are units of beneficial ownership in shares of common stock of the Company that are publicly traded on the Australian Securities Exchange (the \"ASX\") and held by CHESS Depositary Nominees Pty. Limited, a subsidiary of ASX Limited, the company that operates the ASX. Each CDI represents one fully paid share of common stock."}],"balance_after":30555,"source":{"system":"sec-edgar","filing":"0000950157-26-000718","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015726000718/ownership.xml","form_type":"4"}},{"id":1115801,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-06-11T20:27:16.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":2391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2026 annual meeting of stockholders and (b) June 10, 2026. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2026 annual meeting of stockholders and (b) June 10, 2026. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2026 annual meeting of stockholders and (b) June 10, 2026. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":2391,"derivative":{"underlying":"Common Stock","underlying_shares":2391},"source":{"system":"sec-edgar","filing":"0000950157-25-000503","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015725000503/form4.xml","form_type":"4"}},{"id":1120624,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2025-06-06T20:26:12.000Z","date":"2025-06-05","kind":"exercise","planned":false,"acquired":false,"shares":2159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the vesting of restricted stock units granted on June 5, 2024. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the vesting of restricted stock units granted on June 5, 2024. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents the vesting of restricted stock units granted on June 5, 2024. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2159},"source":{"system":"sec-edgar","filing":"0000950157-25-000476","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015725000476/form4.xml","form_type":"4"}},{"id":1120623,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-06T20:26:12.000Z","date":"2025-06-05","kind":"exercise","planned":false,"acquired":true,"shares":2159,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28164,"source":{"system":"sec-edgar","filing":"0000950157-25-000476","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015725000476/form4.xml","form_type":"4"}},{"id":1485839,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-10T22:42:55.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":false,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020.  The award has fully vested.  Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020.  The award has fully vested.  Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020.  The award has fully vested.  Each unit converted into a share of common stock on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2093},"source":{"system":"sec-edgar","filing":"0000950157-24-000878","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015724000878/form4.xml","form_type":"4"}},{"id":1485838,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-10T22:42:55.000Z","date":"2024-06-10","kind":"exercise","planned":false,"acquired":true,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":26005,"source":{"system":"sec-edgar","filing":"0000950157-24-000878","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015724000878/form4.xml","form_type":"4"}},{"id":1487833,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-07T20:54:21.000Z","date":"2024-06-07","kind":"exercise","planned":false,"acquired":false,"shares":3320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents the vesting of restricted stock units granted on June 7, 2023.  The award has fully vested.  Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the vesting of restricted stock units granted on June 7, 2023.  The award has fully vested.  Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents the vesting of restricted stock units granted on June 7, 2023.  The award has fully vested.  Each unit converted into a share of common stock on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3320},"source":{"system":"sec-edgar","filing":"0000950157-24-000863","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015724000863/form4.xml","form_type":"4"}},{"id":1487832,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2024-06-07T20:54:21.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":2159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2025 annual meeting of stockholders and (b) June 5, 2025. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2025 annual meeting of stockholders and (b) June 5, 2025. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2025 annual meeting of stockholders and (b) June 5, 2025. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":2159,"derivative":{"underlying":"Common Stock","underlying_shares":2159},"source":{"system":"sec-edgar","filing":"0000950157-24-000863","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015724000863/form4.xml","form_type":"4"}},{"id":1487831,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-07T20:54:21.000Z","date":"2024-06-07","kind":"exercise","planned":false,"acquired":true,"shares":3320,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":23912,"source":{"system":"sec-edgar","filing":"0000950157-24-000863","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015724000863/form4.xml","form_type":"4"}},{"id":1638772,"issuer":{"id":389,"kind":"organization","name":"Core Scientific, Inc./tx","symbol":"CORZ"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche 2 Warrants","published_at":"2024-02-16T16:18:32.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":42212,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the \"Old Common Stock\"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units (\"RSUs\") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the \"New Common Stock\") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the \"Warrant Agreement\") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the \"Tranche 1 Warrants\") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the \"Tranche 2 Warrants\"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the \"Tranche 1 Exercise Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the \"TEV Triggering Event\"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the \"Warrant Agreement\") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the \"Tranche 1 Warrants\") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the \"Tranche 2 Warrants\"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the \"Tranche 1 Exercise Price\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the \"TEV Triggering Event\"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement."}],"balance_after":42212,"derivative":{"exercise_price":0.01,"expiration_date":"2029-01-23","underlying":"Common Stock, par value $0.00001 per share","underlying_shares":42212},"source":{"system":"sec-edgar","filing":"0000950170-24-016389","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095017024016389/ownership.xml","form_type":"4/A","original_submission_date":"2024-01-25"}},{"id":1638771,"issuer":{"id":389,"kind":"organization","name":"Core Scientific, Inc./tx","symbol":"CORZ"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche 1 Warrants","published_at":"2024-02-16T16:18:32.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":50654,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the \"Old Common Stock\"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units (\"RSUs\") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the \"New Common Stock\") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the \"Warrant Agreement\") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the \"Tranche 1 Warrants\") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the \"Tranche 2 Warrants\"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the \"Tranche 1 Exercise Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the \"TEV Triggering Event\"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer entered into a warrant agreement dated as of January 23, 2024, (the \"Warrant Agreement\") among the Company and Computershare Inc., a Delaware corporation and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company. Pursuant to the Warrant Agreement, the Issuer was authorized to issue (i) an aggregate of 98,381,418 warrants, each exercisable for one share of New Common Stock (the \"Tranche 1 Warrants\") and (ii) an aggregate of 81,984,644 warrants, each exercisable for one share of New Common Stock (the \"Tranche 2 Warrants\"). Each whole Tranche 1 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $6.81 per share (the \"Tranche 1 Exercise Price\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from footnote 4) Each whole Tranche 2 Warrant entitles the registered holder to purchase one whole share of New Common Stock at an exercise price of $0.01 per share at any time following the time the volume weighted average price per share of New Common Stock equals or exceeds $8.72 per share on each trading day for 20 consecutive trading days (the \"TEV Triggering Event\"). The Tranche 1 Exercise Price and the price per share used to determine a TEV Triggering Event are subject to certain adjustments as set forth in the Warrant Agreement."}],"balance_after":50654,"derivative":{"exercise_price":6.81,"expiration_date":"2027-01-23","underlying":"Common Stock, par value $0.00001 per share","underlying_shares":50654},"source":{"system":"sec-edgar","filing":"0000950170-24-016389","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095017024016389/ownership.xml","form_type":"4/A","original_submission_date":"2024-01-25"}},{"id":1638770,"issuer":{"id":389,"kind":"organization","name":"Core Scientific, Inc./tx","symbol":"CORZ"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-02-16T16:18:32.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":40004,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the \"Old Common Stock\"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units (\"RSUs\") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the \"New Common Stock\") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court."}],"balance_after":40004,"source":{"system":"sec-edgar","filing":"0000950170-24-016389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095017024016389/ownership.xml","form_type":"4/A","original_submission_date":"2024-01-25"}},{"id":1638769,"issuer":{"id":389,"kind":"organization","name":"Core Scientific, Inc./tx","symbol":"CORZ"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2024-02-16T16:18:32.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400038,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2022, Core Scientific, Inc. (the \"Issuer\") and certain of its affiliates (collectively, the \"Debtors\") filed voluntary petitions (the \"Chapter 11 Cases\") in the United States Bankruptcy Court for the Southern District of Texas (the \"Bankruptcy Court\") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the \"Plan\"), dated as of January 15, 2024. On January 23, 2024 (the \"Effective Date\"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the \"Old Common Stock\"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock and unvested restricted stock units (\"RSUs\") received new common stock, par value $0.00001 per share at an exchange ratio of 10:1 (the \"New Common Stock\") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization),"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) and, for each share of Old Common Stock, 0.253244 Tranche 1 Warrants and 0.211037 Tranche 2 Warrants (each as defined below). The receipt of the New Common Stock, Tranche 1 Warrants and Tranche 2 Warrants in exchange for Old Common Stock and unvested RSUs was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-016389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095017024016389/ownership.xml","form_type":"4/A","original_submission_date":"2024-01-25"}},{"id":1671191,"issuer":{"id":389,"kind":"organization","name":"Core Scientific, Inc./tx","symbol":"CORZ"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.00001 per share","published_at":"2024-01-25T21:05:26.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":400038,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the \"Old Common Stock\"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock received their pro rata share of new common stock, par value $0.00001 per share (\"New Common Stock\") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization). The receipt of the New Common Stock in exchange for Old Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court."}],"balance_after":400038,"source":{"system":"sec-edgar","filing":"0000950170-24-007642","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095017024007642/ownership.xml","form_type":"4"}},{"id":1671190,"issuer":{"id":389,"kind":"organization","name":"Core Scientific, Inc./tx","symbol":"CORZ"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2024-01-25T21:05:26.000Z","date":"2024-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400038,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2022, Core Scientific, Inc. (the \"Issuer\") and certain of its affiliates (collectively, the \"Debtors\") filed voluntary petitions (the \"Chapter 11 Cases\") in the United States Bankruptcy Court for the Southern District of Texas (the \"Bankruptcy Court\") seeking relief under Chapter 11 of Title 11 of the United States Code. On January 16, 2024, the Bankruptcy Court entered an order confirming the Debtors' Fourth Amended Joint Chapter 11 Plan of Reorganization of Core Scientific, Inc. and its Affiliated Debtors (with Technical Modifications) (the \"Plan\"), dated as of January 15, 2024. On January 23, 2024 (the \"Effective Date\"), the Plan became effective in accordance with its terms and the Debtors emerged from the Chapter 11 Cases."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On the Effective Date, pursuant to the terms of the Plan, the Issuer's common stock outstanding immediately before the Effective Date, par value $0.0001 per share (the \"Old Common Stock\"), was canceled and is of no further force or effect, and in exchange all holders of Old Common Stock received their pro rata share of new common stock, par value $0.00001 per share (\"New Common Stock\") representing, in the aggregate, approximately 21% of the shares of the reorganized Issuer (subject to dilution by awards issuable under a new management incentive plan and shares of New Common Stock issuable upon conversion or exercise of certain secured convertible notes, warrants, contingent value rights and settlement shares issued as part of the reorganization). The receipt of the New Common Stock in exchange for Old Common Stock was involuntary, without consideration and in accordance with the Plan approved by the Bankruptcy Court."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-007642","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095017024007642/ownership.xml","form_type":"4"}},{"id":1859780,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-06-12T23:00:20.000Z","date":"2023-06-12","kind":"exercise","planned":false,"acquired":false,"shares":1928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1928},"source":{"system":"sec-edgar","filing":"0000950157-23-000656","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015723000656/form4.xml","form_type":"4"}},{"id":1859779,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-06-12T23:00:20.000Z","date":"2023-06-10","kind":"exercise","planned":false,"acquired":false,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest on June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest on June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest on June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":2093,"derivative":{"underlying":"Common Stock","underlying_shares":2093},"source":{"system":"sec-edgar","filing":"0000950157-23-000656","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015723000656/form4.xml","form_type":"4"}},{"id":1859778,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-12T23:00:20.000Z","date":"2023-06-12","kind":"exercise","planned":false,"acquired":true,"shares":1928,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20592,"source":{"system":"sec-edgar","filing":"0000950157-23-000656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015723000656/form4.xml","form_type":"4"}},{"id":1859777,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-12T23:00:20.000Z","date":"2023-06-10","kind":"exercise","planned":false,"acquired":true,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":18664,"source":{"system":"sec-edgar","filing":"0000950157-23-000656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015723000656/form4.xml","form_type":"4"}},{"id":1861529,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-06-09T21:22:30.000Z","date":"2023-06-08","kind":"exercise","planned":false,"acquired":false,"shares":3840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents vesting of restricted stock units granted on June 8, 2022. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents vesting of restricted stock units granted on June 8, 2022. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents vesting of restricted stock units granted on June 8, 2022. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3840},"source":{"system":"sec-edgar","filing":"0000950157-23-000640","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015723000640/form4.xml","form_type":"4"}},{"id":1861528,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2023-06-09T21:22:30.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":3320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units are scheduled to vest on June 7, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units are scheduled to vest on June 7, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units are scheduled to vest on June 7, 2024. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":3320,"derivative":{"underlying":"Common Stock","underlying_shares":3320},"source":{"system":"sec-edgar","filing":"0000950157-23-000640","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015723000640/form4.xml","form_type":"4"}},{"id":1861527,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-09T21:22:30.000Z","date":"2023-06-08","kind":"exercise","planned":false,"acquired":true,"shares":3840,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16571,"source":{"system":"sec-edgar","filing":"0000950157-23-000640","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015723000640/form4.xml","form_type":"4"}},{"id":2166082,"issuer":{"id":389,"kind":"organization","name":"Core Scientific, Inc./tx","symbol":"CORZ"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-06T18:32:08.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":400038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") grants. The RSUs vest in four equal annual installments commencing January 19, 2023, provided that the Reporting Person continues to provide service to the Issuer on each vesting date."}],"balance_after":400038,"source":{"system":"sec-edgar","filing":"0001209191-22-048849","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000120919122048849/doc4.xml","form_type":"4"}},{"id":2233592,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-06-14T20:13:49.000Z","date":"2022-06-12","kind":"exercise","acquired":false,"shares":1927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest on June 12, 2023. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest on June 12, 2023. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest on June 12, 2023. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":1928,"derivative":{"underlying":"Common Stock","underlying_shares":1927},"source":{"system":"sec-edgar","filing":"0000950157-22-000709","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015722000709/form4.xml","form_type":"4"}},{"id":2233591,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-14T20:13:49.000Z","date":"2022-06-12","kind":"exercise","acquired":true,"shares":1927,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12731,"source":{"system":"sec-edgar","filing":"0000950157-22-000709","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015722000709/form4.xml","form_type":"4"}},{"id":2236983,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-06-10T20:53:18.000Z","date":"2022-06-10","kind":"exercise","acquired":false,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in two equal installments on each of June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in two equal installments on each of June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in two equal installments on each of June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":4186,"derivative":{"underlying":"Common Stock","underlying_shares":2093},"source":{"system":"sec-edgar","filing":"0000950157-22-000691","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015722000691/form4.xml","form_type":"4"}},{"id":2236982,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-06-10T20:53:18.000Z","date":"2022-06-09","kind":"exercise","acquired":false,"shares":2763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents vesting of restricted stock units granted on June 9, 2021. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents vesting of restricted stock units granted on June 9, 2021. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents vesting of restricted stock units granted on June 9, 2021. The award has fully vested. Each unit converted into a share of common stock on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2763},"source":{"system":"sec-edgar","filing":"0000950157-22-000691","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015722000691/form4.xml","form_type":"4"}},{"id":2236981,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2022-06-10T20:53:18.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":3840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units are scheduled to vest on June 8, 2023. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units are scheduled to vest on June 8, 2023. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units are scheduled to vest on June 8, 2023. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":3840,"derivative":{"underlying":"Common Stock","underlying_shares":3840},"source":{"system":"sec-edgar","filing":"0000950157-22-000691","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015722000691/form4.xml","form_type":"4"}},{"id":2236980,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-10T20:53:18.000Z","date":"2022-06-10","kind":"exercise","acquired":true,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10804,"source":{"system":"sec-edgar","filing":"0000950157-22-000691","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015722000691/form4.xml","form_type":"4"}},{"id":2236979,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-10T20:53:18.000Z","date":"2022-06-09","kind":"exercise","acquired":true,"shares":2763,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8711,"source":{"system":"sec-edgar","filing":"0000950157-22-000691","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015722000691/form4.xml","form_type":"4"}},{"id":2482682,"issuer":{"id":132718,"kind":"organization","name":"TPG Pace Solutions Corp.","symbol":"TPGS"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class F Ordinary Shares, par value $0.0001","published_at":"2021-12-07T16:40:31.000Z","date":"2021-12-03","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the \"Issuer\"), the Class F Ordinary Shares, par value $0.0001 per share (\"Class F Shares\"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Shares\"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the merger of the Issuer with and into Vacasa, Inc. (\"Vacasa\") pursuant to the Business Combination Agreement, as amended, dated as of July 28, 2021, by and among the Issuer, Vacasa and the other parties thereto, the Class F Shares were automatically cancelled, extinguished and converted, on a one-for-one basis, into shares of Class F Common Stock of Vacasa."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the \"Issuer\"), the Class F Ordinary Shares, par value $0.0001 per share (\"Class F Shares\"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Shares\"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Memorandum and Articles of Association, as amended, of TPG Pace Solutions Corp. (the \"Issuer\"), the Class F Ordinary Shares, par value $0.0001 per share (\"Class F Shares\"), of the Issuer, were automatically convertible into Class A Ordinary Shares, par value $0.0001 per share (\"Class A Shares\"), of the Issuer, on a one-for-one basis, at the time of the Issuer's initial business combination, subject to adjustment."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares, par value $0.0001","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-21-147236","document":"tm2134770-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000110465921147236/tm2134770-4_4seq1.xml","form_type":"4"}},{"id":2669422,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2021-06-15T20:35:48.000Z","date":"2021-06-12","kind":"exercise","acquired":false,"shares":1928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in two installments on June 12, 2022 (1,927 units) and June 12, 2023 (1,928 units). Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in two installments on June 12, 2022 (1,927 units) and June 12, 2023 (1,928 units). Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in two installments on June 12, 2022 (1,927 units) and June 12, 2023 (1,928 units). Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":3855,"derivative":{"underlying":"Common Stock","underlying_shares":1928},"source":{"system":"sec-edgar","filing":"0000950157-21-000657","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015721000657/form4.xml","form_type":"4"}},{"id":2669421,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-15T20:35:48.000Z","date":"2021-06-12","kind":"exercise","acquired":true,"shares":1928,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5948,"source":{"system":"sec-edgar","filing":"0000950157-21-000657","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015721000657/form4.xml","form_type":"4"}},{"id":2673003,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2021-06-11T20:35:26.000Z","date":"2021-06-10","kind":"exercise","acquired":false,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in three equal installments on each of June 10, 2022, June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in three equal installments on each of June 10, 2022, June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 10, 2020. The balance of the award is scheduled to vest in three equal installments on each of June 10, 2022, June 10, 2023 and June 10, 2024. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":6279,"derivative":{"underlying":"Common Stock","underlying_shares":2093},"source":{"system":"sec-edgar","filing":"0000950157-21-000629","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015721000629/form4.xml","form_type":"4"}},{"id":2673002,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2021-06-11T20:35:26.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":2763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units are scheduled to vest on June 9, 2022. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units are scheduled to vest on June 9, 2022. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units are scheduled to vest on June 9, 2022. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":2763,"derivative":{"underlying":"Common Stock","underlying_shares":2763},"source":{"system":"sec-edgar","filing":"0000950157-21-000629","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015721000629/form4.xml","form_type":"4"}},{"id":2673001,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-11T20:35:26.000Z","date":"2021-06-10","kind":"exercise","acquired":true,"shares":2093,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4020,"source":{"system":"sec-edgar","filing":"0000950157-21-000629","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000095015721000629/form4.xml","form_type":"4"}},{"id":2986823,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-11-10T16:13:24.000Z","date":"2020-11-06","kind":"sale","acquired":false,"shares":38300,"price":0.1316,"value":5040.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.12 to $0.14, inclusive. Dr. Youngblood will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950138-20-000457","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013820000457/edgar.xml","form_type":"4"}},{"id":3112686,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-12T20:37:52.000Z","date":"2020-06-12","kind":"exercise","acquired":false,"shares":1927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents vesting of one-fourth of restricted stock units granted on June 12, 2019. The balance of the award is scheduled to vest in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":5783,"derivative":{"underlying":"Common Stock","underlying_shares":1927},"source":{"system":"sec-edgar","filing":"0000750004-20-000089","document":"wf-form4_159199425311426.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/750004/000075000420000089/wf-form4_159199425311426.xml","form_type":"4"}},{"id":3112685,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-12T20:37:52.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":8372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units are scheduled to vest in four equal annual installments beginning on June 10, 2021. Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":8372,"derivative":{"underlying":"Common Stock","underlying_shares":8372},"source":{"system":"sec-edgar","filing":"0000750004-20-000089","document":"wf-form4_159199425311426.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/750004/000075000420000089/wf-form4_159199425311426.xml","form_type":"4"}},{"id":3112684,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T20:37:52.000Z","date":"2020-06-12","kind":"exercise","acquired":true,"shares":1927,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1927,"source":{"system":"sec-edgar","filing":"0000750004-20-000089","document":"wf-form4_159199425311426.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000075000420000089/wf-form4_159199425311426.xml","form_type":"4"}},{"id":3147534,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-05-15T16:59:23.000Z","date":"2020-05-13","kind":"tax_withholding","acquired":false,"shares":8729,"price":2.96,"value":25837.84,"ownership":{"direct":true},"balance_after":38300,"source":{"system":"sec-edgar","filing":"0000950138-20-000269","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013820000269/edgar.xml","form_type":"4"}},{"id":3361467,"issuer":{"id":4999,"kind":"organization","name":"Accel Entertainment, Inc.","symbol":"ACEL"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class F Ordinary Shares","published_at":"2019-11-22T16:17:28.000Z","date":"2019-11-20","kind":"sale","acquired":false,"shares":40000,"price":10.22,"value":408800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the \"Issuer\"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the \"Issuer\"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Amended and Restated Memorandum and Articles of Association of TPG Pace Holdings Corp. (renamed as Accel Entertainment, Inc., the \"Issuer\"), the Class F Ordinary Shares, par value $0.0001 per share, of the Issuer had been automatically convertible into Class A Ordinary Shares, par value $0.0001 per share, of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-19-027961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000089924319027961/doc4.xml","form_type":"4"}},{"id":3493539,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-12T22:41:28.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":7710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units are scheduled to vest beginning on June 12, 2020 (1,927 shares) and the balance in three installments on June 12, 2021 (1,928 shares), June 12, 2022 (1,927 shares) and June 12, 2023 (1,928 shares). Each unit converts into a share of common stock on a one-for-one basis."}],"balance_after":7710,"derivative":{"underlying":"Common Stock","underlying_shares":7710},"source":{"system":"sec-edgar","filing":"0000750004-19-000061","document":"wf-form4_156037927321233.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000075000419000061/wf-form4_156037927321233.xml","form_type":"4"}},{"id":3521482,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-17T07:16:13.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":19396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":47029,"source":{"system":"sec-edgar","filing":"0000950138-19-000318","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013819000318/edgar.xml","form_type":"4"}},{"id":3521481,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-17T07:16:13.000Z","date":"2019-05-15","kind":"tax_withholding","acquired":false,"shares":8527,"price":15.21,"value":129695.67,"ownership":{"direct":true},"balance_after":27633,"source":{"system":"sec-edgar","filing":"0000950138-19-000318","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013819000318/edgar.xml","form_type":"4"}},{"id":3850385,"issuer":{"id":9758,"kind":"organization","name":"Light & Wonder, Inc.","symbol":"ASX:LNW"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-08-08T20:34:50.000Z","date":"2018-08-06","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options are scheduled to become exercisable in four equal annual installments beginning on August 6, 2019."}],"balance_after":10000,"derivative":{"exercise_price":37.35,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000750004-18-000178","document":"wf-form4_153376047447761.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/750004/000075000418000178/wf-form4_153376047447761.xml","form_type":"4"}},{"id":3926068,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-05-18T16:53:11.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":18947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":36160,"source":{"system":"sec-edgar","filing":"0000950138-18-000431","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013818000431/edgar.xml","form_type":"4"}},{"id":4016091,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-03-05T16:37:40.000Z","date":"2018-03-01","kind":"tax_withholding","acquired":false,"shares":2576,"price":15.68,"value":40391.68,"ownership":{"direct":true},"balance_after":17213,"source":{"system":"sec-edgar","filing":"0000950138-18-000218","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013818000218/edgar.xml","form_type":"4"}},{"id":4147811,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-11-30T09:08:18.000Z","date":"2017-11-28","kind":"purchase","acquired":true,"shares":4560,"price":21.94,"value":100046.4,"ownership":{"direct":true},"balance_after":19789,"source":{"system":"sec-edgar","filing":"0000950138-17-000770","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013817000770/edgar.xml","form_type":"4"}},{"id":4195210,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-10-03T17:11:55.000Z","date":"2017-10-01","kind":"tax_withholding","acquired":false,"shares":476,"price":37.37,"value":17788.12,"ownership":{"direct":true},"balance_after":15229,"source":{"system":"sec-edgar","filing":"0000950138-17-000707","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013817000707/edgar.xml","form_type":"4"}},{"id":4386605,"issuer":{"id":177842,"kind":"organization","name":"Pace Holdings Corp.","symbol":"PACE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class F Ordinary Shares","published_at":"2017-03-14T18:44:59.000Z","date":"2017-03-10","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":false,"nature":"See Explanation of Responses"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the merger of Pace Holdings Corp. (the \"Issuer\") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the \"Business Combination\"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the \"Class F Shares\"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the merger of Pace Holdings Corp. (the \"Issuer\") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the \"Business Combination\"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the \"Class F Shares\"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the merger of Pace Holdings Corp. (the \"Issuer\") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the \"Business Combination\"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the \"Class F Shares\"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the merger of Pace Holdings Corp. (the \"Issuer\") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the \"Business Combination\"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the \"Class F Shares\"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"In connection with the merger of Pace Holdings Corp. (the \"Issuer\") with and into New PACE Holdings Corp. and a series of related transactions (collectively, the \"Business Combination\"), Dr. Kneeland Youngblood disposed of his Class F ordinary shares, par value $0.0001 (the \"Class F Shares\"), of the Issuer ultimately receiving ordinary shares, par value (euro) 0.10 per share, of Playa Hotels & Resorts N.V. Pursuant to the Amended and Restated Memorandum and Articles of Association of the Issuer, the Class F Shares were to automatically convert into Class A ordinary shares, par value $0.0001, of the Issuer at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), this filing shall not be deemed an admission that Dr. Youngblood is, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000903423-17-000191","document":"youngblood4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000090342317000191/youngblood4.xml","form_type":"4"}},{"id":4404964,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-03-03T18:48:11.000Z","date":"2017-03-01","kind":"tax_withholding","acquired":false,"shares":2286,"price":51.55,"value":117843.3,"ownership":{"direct":true},"balance_after":15705,"source":{"system":"sec-edgar","filing":"0000950138-17-000264","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013817000264/edgar.xml","form_type":"4"}},{"id":4404963,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2017-03-03T18:48:11.000Z","date":"2017-03-01","kind":"grant","acquired":true,"shares":5723,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of March 1, 2018. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":17991,"source":{"system":"sec-edgar","filing":"0000950138-17-000264","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013817000264/edgar.xml","form_type":"4"}},{"id":4587445,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":39095,"kind":"person","name":"YOUNGBLOOD DR KNEELAND","position":1,"cik":"0001137820","reported_name":"YOUNGBLOOD DR KNEELAND","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2016-10-04T10:10:57.000Z","date":"2016-10-01","kind":"grant","acquired":true,"shares":1057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units that vest in their entirety as of October 1, 2017. The restricted stock units settle in ordinary shares upon vesting."}],"balance_after":12268,"source":{"system":"sec-edgar","filing":"0000950138-16-001380","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137820/000095013816001380/edgar.xml","form_type":"4"}}]}